Organigram Global Inc. (OGI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Organigram Global Inc. (OGI) Healthcare & Pipeline Overview

Organigram Global Inc. is a Canadian cannabis producer offering medical and recreational products, including flowers, oils, edibles, and concentrates. With a focus on innovation and brand development, Organigram competes in the evolving Canadian cannabis market, navigating regulatory changes and shifting consumer preferences to maintain market share.

What Is the Investment Thesis for OGI?

Organigram Global Inc. presents a mixed investment thesis. The company's focus on both medical and recreational cannabis markets in Canada provides diversification. The company's P/E ratio stands at 14.04, and the profit margin is 6.5%. Organigram's ability to innovate with new product formats and expand its market share in key provinces will be critical. However, the cannabis industry is subject to evolving regulations and intense competition, which could impact Organigram's profitability and growth. Investors should monitor the company's ability to maintain its gross margin of 6.8% and navigate the competitive landscape.

Based on FMP financials and quantitative analysis

OGI Key Highlights

Market capitalization of $169M reflects investor valuation of Organigram's future growth potential in the cannabis market.

• P/E ratio of 14.04 suggests the company is generating profits relative to its stock price.
• Gross margin of 6.8% indicates the profitability of Organigram's core operations after accounting for the cost of goods sold.
• Profit margin of 6.5% demonstrates the company's ability to control expenses and generate net income.
• Beta of 1.87 indicates that the stock is more volatile than the overall market.

Who Are OGI's Competitors?

OGI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OGI's Key Strengths?

Diversified product portfolio.

• Established brands in the Canadian market.
• Focus on innovation and product development.
• Distribution network across Canada.

What Are OGI's Weaknesses?

Relatively low gross margin.

• Intense competition in the Canadian cannabis market.
• Dependence on regulatory approvals.
• Limited international presence.

What Could Drive OGI Stock Higher?

Launch of new cannabis-infused beverage products in Q3 2026, targeting a broader consumer base.

• Expansion of distribution network to new provinces in Canada, increasing product availability.
• Development of innovative cannabis strains with higher THC and CBD levels, catering to specific consumer preferences.

What Are the Key Risks for OGI?

Financial-distress signal — its Altman Z-Score of 0.33 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-6.8%) — the business is not currently generating profit on shareholder capital.
• Changes in cannabis regulations that could impact production, distribution, and sales.
• Increased competition from other cannabis companies, leading to pricing pressures and reduced market share.
• Fluctuations in cannabis prices due to supply and demand imbalances.
• Negative perception of cannabis among some consumers, limiting market growth.
• Product recalls or safety concerns that could damage the company's reputation.

What Are the Growth Opportunities for OGI?

• Expansion of Edibles and Derivative Products: Organigram can capitalize on the growing demand for cannabis edibles and derivative products. The market for edibles is projected to reach $2.5 billion by 2028. By introducing innovative and appealing edible products, Organigram can attract new customers and increase its market share. This includes developing new flavors, formats, and dosages to cater to diverse consumer preferences. The timeline for significant revenue contribution is estimated within the next 2-3 years.
• Strategic Partnerships and Acquisitions: Organigram can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other cannabis companies or acquiring smaller players can provide access to new technologies, brands, and distribution networks. This can accelerate Organigram's growth and enhance its competitive position. The timeline for realizing benefits from such partnerships or acquisitions is typically 1-2 years.
• International Expansion: Organigram can explore opportunities to expand its operations into international markets. As more countries legalize cannabis for medical or recreational use, there is potential for Organigram to establish a presence in new regions. This could involve exporting products, establishing joint ventures, or acquiring local cannabis companies. The timeline for significant international revenue is estimated within the next 3-5 years.
• Focus on Medical Cannabis Market: Organigram can strengthen its position in the medical cannabis market by developing specialized products and services for patients. This includes conducting clinical research, partnering with healthcare providers, and offering personalized treatment plans. The medical cannabis market is expected to grow as more patients and doctors recognize the therapeutic benefits of cannabis. The timeline for increased revenue from medical cannabis is estimated within the next 1-2 years.
• Development of Innovative Consumption Methods: Organigram can invest in research and development to create innovative cannabis consumption methods. This includes developing new vaporizers, transdermal patches, and other delivery systems that offer improved convenience, dosage control, and bioavailability. By staying ahead of the curve in terms of technology and innovation, Organigram can attract early adopters and differentiate itself from competitors. The timeline for launching new consumption methods is typically 2-3 years.

What Are OGI's Competitive Advantages?

• Established brands in the Canadian cannabis market.
• Diversified product portfolio catering to different consumer preferences.
• Strategic partnerships with other cannabis companies.
• Focus on innovation and product development.

What Does OGI Do?

Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada. The company operates through its subsidiaries to produce and sell cannabis and cannabis-derived products in the Canadian market. Organigram serves both the medical and recreational cannabis sectors. For medical patients and veterans, Organigram provides cannabis flowers, cannabis oils, and vaporizers. In the adult-use recreational market, the company offers products under brands like Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour. These brands encompass a range of product types, including dried cannabis flower, pre-rolls, cannabis derivative based products, cannabis edibles, and concentrates. Organigram also engages in wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. The company distributes its products through online and telephone channels, ensuring accessibility for a wide customer base across Canada. Organigram's diversified product portfolio and multi-channel distribution strategy position it as a key player in the Canadian cannabis industry.

What Products and Services Does OGI Offer?

• Produces and sells cannabis flowers for medical and recreational use.
• Manufactures and distributes cannabis oils for various applications.
• Offers vaporizers for cannabis consumption.
• Develops and markets cannabis edibles products.
• Creates and sells cannabis concentrates.
• Engages in wholesale shipping of cannabis products to retailers and wholesalers.

How Does OGI Make Money?

• Cultivation and production of cannabis plants.
• Manufacturing of cannabis-derived products.
• Distribution of products through online and telephone channels.
• Wholesale shipping to retailers and wholesalers.

What Industry Does OGI Operate In?

Organigram operates in the rapidly evolving Canadian cannabis industry. The market is characterized by increasing competition, evolving regulations, and shifting consumer preferences. Companies like Organigram are focused on product innovation, brand development, and efficient operations to gain market share. The Canadian cannabis market is expected to continue to grow, driven by increasing acceptance and legalization. However, companies face challenges such as pricing pressures and regulatory compliance. Organigram's ability to differentiate itself through unique product offerings and efficient distribution will be crucial for success.

Who Are OGI's Key Customers?

• Medical cannabis patients seeking therapeutic relief.
• Adult-use recreational cannabis consumers.
• Retailers selling cannabis products to consumers.
• Wholesalers distributing cannabis products to retailers.

Return on equity for Organigram Global Inc. stands at -6.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.3%, the inverse of the P/E and a quick read on earnings relative to price.

Organigram Global Inc. (OGI) Valuation Context

Valued at $169M, OGI is classified as a micro-cap stock. Relative to its peer group, OGI's quantitative score of 44/100 is below the peer average of 55/100.

Company Profile

Organigram Global Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO James H. Yamanaka. OGI has traded publicly since 2019.

Organigram Global Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.33 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Organigram Global Inc. revenue of about $239.8M for fiscal 2026, with EPS near $0.09. The estimate reflects 4 contributing analysts.

OGI Financials

OGI Latest News

No recent news available for OGI.

OGI Analyst Consensus

OGI MoonshotScore

What Investors Ask About Organigram Global Inc. (OGI) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources